NCT00251511View on ClinicalTrials.gov

A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome

PHASE2TerminatedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

January 31, 2006

Study Completion Date

May 31, 2007

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

Arsenic Trioxide

Trial Locations (1)

77042

Veeda Oncology, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Cephalon

INDUSTRY

lead

Veeda Oncology

OTHER